Contact The Gross Law Firm by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Regeneron Pharmaceuticals, alleging that the company made materially false and misleading statements regarding its pricing practices for Eylea, which may have artificially inflated its reported sales figures [1]. Group 1: Allegations Against Regeneron - The lawsuit claims that Regeneron paid credit card fees to distributors to prevent them from charging Eylea customers more for credit card usage [1]. - These payments allegedly subsidized the prices customers paid when using credit cards, leading to a price concession that lowered Eylea's selling price [1]. - The complaint states that Regeneron's price concessions provided a competitive advantage due to retina practices being sensitive to higher prices for anti-VEGF medications [1]. - As a result of these actions, Regeneron is accused of misleadingly boosting reported Eylea sales and overstating the Average Selling Price (ASP) reported to federal agencies, violating the False Claims Act [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as November 2, 2023, to October 30, 2024, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is March 10, 2025, and there is no cost or obligation to participate in the case [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].